Macrovica

Macrovica is a pre-clinical stage biotechnology company focused on the development of next-generation, in vivo macrophage-targeted therapies for the treatment of solid tumors. The company leverages a proprietary lipid nanoparticle (LNP) platform designed to selectively deliver mRNA to macrophages, enabling the reprogramming of these cells directly within the tumor microenvironment. By converting immunosuppressive tumor-associated macrophages into active anti-tumor agents, Macrovica aims to provide a more scalable and effective alternative to traditional ex vivo cell therapies. Founded by leaders in the field of macrophage biology and engineered cell therapy, the company is currently advancing its platform toward clinical applications in oncology.